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First Trimester Plasma Glucose Values in Women without Diabetes are
Associated with Risk for Congenital Heart Disease in Offspring
Emmi I. T. Helle, MD, PhD, MSc (Econ)1,2, Preston Biegley, BS3, Joshua W. Knowles, MD, PhD1, Joseph B. Leader, BA3,
Sarah Pendergrass, PhD MS3, Wei Yang, MS4, Gerald R. Reaven, MD1, Gary M. Shaw, DrPh4,
Marylyn Ritchie, PhD3, and James R. Priest, MD1,4,5
In a retrospective study of 19 171 mother-child dyads, elevated random plasma glucose values during early preg-
nancy were directly correlated with increased risk for congenital heart disease in offspring. Plasma glucose levels
proximal to the period of cardiac development may represent a modifiable risk factor for congenital heart disease
in expectant mothers without diabetes. (J Pediatr 2018;195:275-8).
M aternal diabetes has long been recognized to be arisk factor for congenital heart disease in offspring.1,2Despite the different pathophysiological mecha-
nisms, both type 1 and type 2 diabetes con-
tribute to the risk of congenital heart disease3
and although attenuated in women with im-
proved glucose control, the risk of congeni-
tal heart disease does not revert to baseline.4,5
Population studies suggest the presence of acute diabetic com-
plications during pregnancy significantly increase risk of all
types of congenital heart diseases in offspring.1 Interestingly,
a recent case-control study in mothers without diabetes dis-
played elevated random plasma glucose values during the
second trimester in mothers of offspring with tetralogy of Fallot
compared with mothers whose offspring did not have con-
genital heart disease.6 These findings suggest that risk of con-
genital heart disease in the fetus conferred by maternal diabetes
may be related to greater variations in plasma glucose levels
in mothers with diabetes rather than, to long-term glucose
values (glycated hemoglobin A1c), plasma insulin level, or a
clinical diagnosis of diabetes. In addition, it raises the ques-
tion of whether transient plasma glucose elevations even in
mothers without diabetes could predispose offspring for con-
genital heart disease.
Though studies of glucose metabolism performed during
the second trimester appear to be strongly linked to glucose
metabolism during both the periconceptional period and first
trimester,7-9 cardiac morphogenesis occurs during the first tri-
mester between gestational weeks 4-10.10 Most clinical mea-
surements of glucose metabolism such as the oral glucose
tolerance test (OGTT) are typically performed during the
second trimester after the heart has already formed. There-
fore, we sought to determine if random nonfasting plasma
glucose levels measured proximally to the period of cardiac de-
velopment encompassing the first trimester were related to the
risk of congenital heart disease both in mothers with diabe-
tes and without diabetes.
Methods
We assembled a retrospective multi-institutional cohort of
19 107 mother-child dyads of mothers aged
16 years or older for which prenatal infor-
mation and postnatal diagnoses were avail-
able (Stanford Healthcare years 2009-2014
[n = 9742] and Geisinger Health System years
2010-2015 [n = 9365]).We excluded offspring with a diagno-
sis of aneuploidy or 22q11.2 deletion syndrome,multiple preg-
nancies, and women with extreme body mass index (BMI)
measures (<15 or >50). Estimated dates of conception were
interpolated in a hierarchical fashion from 280 days prior to
birth, unless more specific data was available from Interna-
tional Classification of Diseases, Ninth Revision (ICD-9) codes
(765.11-765.19) for prematurity status. Given some ambigu-
ity in estimation of exact timing of laboratory measure-
ments during pregnancy, we obtained all random plasma
glucose measurements performed between 4 weeks prior to the
estimated date of conception until the end of the 14th gesta-
tional week, and also results of the 1-hour OGTT typically com-
pleted during late second trimester. If multiple measurements
were available, we selected the single highest value for analy-
sis as delayed separation of the plasma can decrease the glucose
value of the sample. We included plasma glucose measure-
ments in our analysis, and specifically excluded glucose mea-
surements designated as “fasting”or from glucose tolerance tests
within the electronic medical record. Because insulin values
are rarely measured as a component of routine clinical care,
we did not incorporate insulin or other measures of insulin
BMI Body mass index
ICD-9 International Classification of Diseases, Ninth Revision
OGTT Oral glucose tolerance test
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resistance within our analysis other than OGTT. A
diagnosis of congenital heart disease was defined by the pres-
ence of any type of congenital heart disease (ICD-9 codes 745.0-
747.49) in the offspring. For individuals with OGTT and
glucose measures, we performed logistic regression, and ad-
justed the model for known maternal risk factors for off-
spring with congenital heart disease, including presence of
pregestational diabetes (defined by the presence of ICD-9 codes
250-250.93), prepregnancy BMI, and maternal age at deliv-
ery. In a sensitivity analysis, we excluded mothers with
pregestational diabetes. Power calculations were performed as-
suming an average glucose value of 89.3 mg/dL with a SD of
6.2 mg/dL, demonstrating that in a group of 200 cases, 2000
controls displayed 80% power to detect an effect of 0.18 SDs
between the 2 groups. Regression models were constructed
using the R language for statistical computing.
Results
Review of electronic medical records at both study institu-
tions identified 811 congenital heart disease-affected preg-
nancies and 18 296 without congenital heart disease. At the
Stanford site where detailed diagnostic information was avail-
able for review, all categories of congenital heart disease were
represented with one-half of cases (49.9%, n = 223) consti-
tuting isolated ventricular or atrial septal defects. Relative to
the Geisinger cohort, which is a community-based health
system, the mothers at the Stanford cohort were older, with
higher BMI, and a greater burden of prepregnancy diabetes
(Table I). Plasma glucose values were measured at least once
in 11.9%, and OGTT in 49.7% of mothers.Mothers with mea-
sured plasma glucose values were younger thanmothers without
measurements (median 26 vs 28 years), and the same applied
for OGTT values (median 26 vs 30 years).
Among the women with relevant clinical measurements,
higher plasma glucose (OR 1.08 per 10 mg/dL increase in
glucose, 95% CI 1.03-1.12, P < .001) and higher 1-hour OGTT
values (OR 1.06, 95% CI 1.02-1.10, P = .002) were both asso-
ciated with increased risk for congenital heart disease off-
spring in unadjusted logistic models. After adjustment for
clinical correlates of glucose metabolism including maternal
age, prepregnancy BMI, and the presence of pre-existing ma-
ternal diabetes (Table II), higher random first trimester plasma
glucose values remained associated with increased risk for con-
genital heart disease (aOR 1.08 per 10 mg/dL increase in
Table I. Measured variables by enrollment site
Stanford Geisinger
n = 9742 n = 9365
Age, y, median 31 25
Congenital heart disease, n (% of total) 447 (4.6%) 364 (3.9%)
Prepregnancy diabetes, n (% of total) 60 (0.6%) 14 (0.1%)
Prepregnancy BMI, median (n, % total with measurements) 28.1 (9643, 99.0%) 25.1 (6112, 65.2%)
Early plasma glucose mg/dL, median (n, % total with measurements) 92 (903, 9.2%) 89 (1389, 14.8%)
OGTT 1 h value mg/dL, median (n, % total with measurements) 122 (1825, 18.7%) 112 (7686, 82.1%)
More than 1 glucose measurement (n, % of those with glucose measurements) 5 (0.6%) 386 (27.8%)
More than 1 OGTT measurement (n, % of those with glucose measurements) 306 (16.7%) 100 (1.3%)
Table II. Logistic regression models for glucose and 1 hour OGTT and risk for congenital heart disease in the off-
spring including and excluding mothers with diabetes
Models for glucose
Including all mother-infant
dyads (n = 2233)
Excluding mother-infant dyads with
pre-existing maternal DM (n = 2204)
OR (95% CI) P value OR (95% CI) P value
Glucose (mg/dL/10) 1.079 (1.023-1.131) .003 1.086 (1.023-1.143) .003
BMI 1.007 (0.976-1.037) .656 1.004 (0.974-1.035) .775
Maternal age 1.005 (0.972-1.038) .77 1.007 (0.974-1.040) .685
Maternal DM 0.687 (0.085-3.124) .674 n/a n/a
Models for OGTT
Including all mother-infant
dyads (n = 7147)
Excluding mother-infant dyads with
pre-existing maternal DM (n = 7142)
OR (95% CI) P value OR (95% CI) P value
OGTT 1 h (mg/dL) 1.003 (0.998-1.007) .214 1.003 (0.998-1.007) .214
BMI 1.006 (0.986-1.025) .572 1.006 (0.986-1.025) .572
Maternal age 1.029 (1.009-1.050) .004 1.029 (1.009-1.050) .004
Maternal DM 0.000 (NA-29.120) .976 n/a n/a
Model simultaneously included OGTT, maternal prepregnancy BMI, maternal age, and maternal diagnosis for diabetes mellitus (where applicable).
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glucose, 95% CI 1.02-1.13, P = .003) and the association with
1-hour OGTT values was elevated but not statistically signifi-
cant (aOR 1.03, 95% CI 0.98-1.07, P = .214). In a sensitivity
analysis excluding women with a pre-existing diagnosis of dia-
betes (n = 74), the positive association between a random
plasma glucose value with risk for congenital heart disease
among offspring was essentially unchanged (aOR 1.09, 95%
CI 1.02-1.14, P = .003) (Table II).
Discussion
Our observations demonstrate that higher random plasma
glucose values measured during early pregnancy correlate with
increased risk for congenital heart disease in offspring of
mothers who do not have diabetes. Furthermore, plasma glucose
measured during early pregnancy was more associated with
risk for congenital heart disease in offspring, compared with
the OGTT which is often used to risk-stratify pregnancies for
fetal-echocardiographic screening.
Previous clinical observations detect increased risk for con-
genital heart disease in offspring even in mothers with dia-
betes with well controlled glucose levels,4,5 suggesting that the
risk to offspring may be related to the variation in the plasma
glucose levels. Although a lower glycated hemoglobin A1c value
reflects lower average glucose levels in the long term, fluctua-
tion in glucose levels are likely higher in mothers with diabe-
tes than in mothers without diabetes. Transient high glucose
is known to cause persistent epigenetic changes and altered gene
expression in vascular cells during subsequent normoglycemia.11
As cardiac development occurs early in pregnancy, and many
important complex structures are formed during a short period
of time, it is possible that even short elevations in glucose levels
during critical time points can be enough to disturb cardiac
development.
The exact mechanisms by which high glucose may impact
cardiac development are not yet clear. Maternal diabetes has
been most strongly associated with conotruncal defects, such
as tetralogy of Fallot.3 High glucose and augmented oxida-
tive stress have been observed to inhibit migration of neural
crest derived cells from the neural tube in study animals, leading
to congenital heart disease.12,13 Thus, if the results from animal
studies can be generalized to humans, transient elevations in
glucose values during critical periods of cardiac develop-
ment might potentially disturb the cardiac neural crest mi-
gration even in embryos of mothers without diabetes and
contribute to the risk of congenital heart disease in the fetus.
Prediabetes is observed in as many as 28% of women of
childbearing age.14 Given that increased risk for congenital heart
disease continues to be measurable in women without a pre-
existing diagnosis of diabetes both previously and now more
fully in the data reported here, the contribution of maternal
prediabetes to risk of congenital heart disease in offspring re-
quires careful assessment in large prospective cohort studies.
As plasma glucose levels are correlated with modifiable be-
haviors such weight, physical activity, and dietary habits, con-
firming these results in larger studies could provide additional
data for pre- and early pregnancy health recommendations as
a strategy to optimize the outcomes of pregnancy.
As a retrospective study, these findings are limited by bias
inherent in selection of patients with glucose measurements
and the ascertainment challenges inherent to working with data
obtained from electronic medical records that did not include
information on known risk factors for congenital heart disease
such as maternal smoking, alcohol consumption, or infec-
tion. Early pregnancy plasma glucose measurements were
present for only 13% of the mother-infant dyads, and the clini-
cal reasoning for obtaining the glucose value was unknown,
thus, some values may be fasting or from other controlled states.
The Geisinger cohort had individuals with multiple glucose
measurements, which may be related to a bias toward more
readily availability measurements from an integrated inpatient-
outpatient electronic medical record. Indeed, the cohorts dis-
played differences attributable to the different roles that the
2 institutions play within their respective healthcare markets.
The older maternal age, higher BMI, higher rates of preexist-
ing diabetes and congenital heart disease are illustrative of a
“higher-risk”maternal cohort, which reflects the role of Stan-
ford Healthcare as a regional and statewide quaternary refer-
ral center. In contrast, the Geisinger cohort may represent a
less selective population with an “average risk” for adverse out-
comes. However, glucose values were measured in similar fre-
quencies in pregnancies with or without congenital heart disease
(12.3% of dyads with congenital heart disease, 13.6% of dyads
without congenital heart disease), which does not suggest se-
lection bias related to clinical suspicion of congenital heart
disease or any known correlates. The overall size of the cohort
was not adequately powered to characterize the risk for spe-
cific congenital heart disease malformations. As such, larger
prospective studies are necessary to confirm the generalizability
of these findings.
A random plasma glucose value performed early in preg-
nancy may be a marker for risk of congenital heart disease in
offspring in mothers without diabetes. Though strongly in-
fluenced by common genetic loci, plasma glucose levels are cor-
related with modifiable behaviors such as weight, physical
activity, and dietary habits. If confirmed in large population
based studies, plasma glucose values may represent a modi-
fiable risk factor for congenital heart disease in expectant
mothers and women planning pregnancy and a biomarker ap-
plicable to risk-stratification of pregnant mothers for prena-
tal echocardiography screening for congenital heart disease in
the fetus. ■
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